Dr. John D. Gabriel, MD
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (1978)
- Years since graduation
- 48
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 466
Licensed in Texas since 1978, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1978Medical school: University of Texas Southwestern Medical School at Dallas
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
TX license F1559 (first issued 1978; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- North Hills Family Practice, PA (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 466
- Services billed
- 10,933
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 816 | 382 |
| Established patient office or other outpatient visit, 20-29 minutes | 312 | 219 |
| Automated urinalysis test | 263 | 185 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 132 | 132 |
| Detection test by immunoassay with direct visual observation for influenza virus | 128 | 54 |
| Injection of drug or substance under skin or into muscle | 106 | 71 |
| Injection, methylprednisolone acetate, 80 mg | 79 | 60 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 75 | 62 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 48 | 40 |
| X-ray of chest, 2 views | 39 | 36 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 54 payments worth $2,891 in total to this clinician.
| Chiesi USA, Inc. | $2,046 |
|---|---|
| AbbVie Inc. | $167 |
| Novo Nordisk Inc | $140 |
| GlaxoSmithKline, LLC. | $124 |
| Lilly USA, LLC | $103 |
| Exact Sciences Corporation | $52.05 |
| Phathom Pharmaceuticals, Inc. | $47.25 |
| Pfizer Inc. | $46.50 |
| Travel and Lodging | $1,957 |
|---|---|
| Food and Beverage | $933 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Chiesi USA, Inc. Jan 24, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $1,957 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 5 companies. The companies reported $851,657 in research payments for these studies, mostly to the institutions running them.
- A master protocol to investigate the efficacy and safety of orforglipron once daily in participants with hypertension and obesity or overweight: randomized, double-blind, placebo-controlled trials (attain-hypertension…
Eli Lilly and Company - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients
Novartis Pharmaceuticals Corporation - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
Novartis Pharmaceuticals Corporation - A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD
Novartis Pharmaceuticals Corporation - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
AbbVie Inc. · Active, not recruiting · NCT06063967 - A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
Ardelyx, Inc. · Recruiting · NCT07382167
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.